Skip to main content
Premium Trial:

Request an Annual Quote

Ribozyme Forms New Company In Germany


BERLIN--Ribozyme Pharmaceuticals of Boulder, Colo., has formed a new company here with help from private sector investments and funding commitments from the German government as part of the government's initiative to encourage new biotechnology investments in the country. The investments could provide in excess of $50 million for five years.

The new company, Atugen Biotechnology, will utilize Ribozyme's proprietary ribozyme and related technologies as a continuation of Ribozyme's target validation and discovery business. Atugen's primary goal will be to accelerate in vivo validation of human health therapeutic targets. Ribozyme said it expects the technologies to be acquired or developed by Atugen, combined with its potentially substantial initial capitalization, will allow that company to make significant improvements in the speed and specificity with which new therapeutic targets can be identified and validated.

Technologies the company expects to add include transgenic animals, the use of DNA chips for differential expression, and bioinformatics.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.